Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57<sup>CDKN1C</sup> and TP53INP1 in mantle cell lymphoma
<b>Objective</b> To explore the effect of dysregulation of epigenetic regulator EZH1 and EZH2 on the proliferation in MCL and the underlying mechanisms.<b>Methods</b> In this study, we elucidated the role of EZH1 and EZH2 overexpression by immunohistochemistry and correlated...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
China Anti-Cancer Association
2019-09-01
|
| Series: | Cancer Biology & Medicine |
| Subjects: | |
| Online Access: | http://www.cancerbiomed.org/index.php/cocr/article/view/1451 |
| _version_ | 1828355379456638976 |
|---|---|
| author | Wei Li Chengfeng Bi Yating Han Tian Tian Xianhuo Wang Huijing Bao Xiaoying Xu Xuhan Zhang Lu Liu Weiwei Zhang Hai Gao Huaqing Wang Huilai Zhang Bin Meng Xi Wang Kai Fu |
| author_facet | Wei Li Chengfeng Bi Yating Han Tian Tian Xianhuo Wang Huijing Bao Xiaoying Xu Xuhan Zhang Lu Liu Weiwei Zhang Hai Gao Huaqing Wang Huilai Zhang Bin Meng Xi Wang Kai Fu |
| author_sort | Wei Li |
| collection | DOAJ |
| description | <b>Objective</b> To explore the effect of dysregulation of epigenetic regulator EZH1 and EZH2 on the proliferation in MCL and the underlying mechanisms.<b>Methods</b> In this study, we elucidated the role of EZH1 and EZH2 overexpression by immunohistochemistry and correlated them to clinical outcome in 41 MCL patients. Quantitative real-time PCR and Western blot were applied to confirm the level of EZH1 and EZH2 in well-characterized MCL cell lines which were compared to those of na?ve B cells. Then we manipulated the expression of EZH1 and EZH2 in MCL cells using CRISPR/Cas9 system to directly investigate their functional roles in MCL. We also evaluated the effect of two small molecule selective inhibitors, EPZ005687 and UNC1999, on MCL cell proliferation, cell cycle distribution and apoptosis <i>in vitro</i>. Finally, we performed RNA-sequencing (RNA-Seq) and Chromatin immunoprecipitation (ChIP) assay to further gain insight into the underlying molecular mechanisms.<b>Results</b> We found that EZH2 protein is overexpressed in approximately half of this cohort of MCL cases. More importantly, the overexpression of EZH2 is associated with poor OS in the patients. Nevertheless, simple EZH2 depletion <i>in vitro</i> has little impact on the viability of MCL cells, predominantly because of the consequent up-regulation of EZH1. Consistently, UNC1999, a dual EZH1/2 inhibitor, unlike the EZH2 selective inhibitor EPZ005687, exerts a potent inhibitory effect on MCL cells. Furthermore, we discover <i>CDKN1C</i> and <i>TP53INP1</i> as the two important cell cycle regulators, the expression of which are repressed by EZH1/2 mediated epigenetic regulation and are restored by EZH1/2 dual inhibition.<b>Conclusions</b> Our study suggests that EZH2 participates in the pathogenesis of MCL which may serve as a potential biomarker for prognosis prediction. The dual inhibition of EZH1/2 is a promising therapeutic strategy for MCL. |
| first_indexed | 2024-04-14T02:40:07Z |
| format | Article |
| id | doaj.art-6eb64af8950648c5949c2bcf8641d6b8 |
| institution | Directory Open Access Journal |
| issn | 2095-3941 2095-3941 |
| language | English |
| last_indexed | 2024-04-14T02:40:07Z |
| publishDate | 2019-09-01 |
| publisher | China Anti-Cancer Association |
| record_format | Article |
| series | Cancer Biology & Medicine |
| spelling | doaj.art-6eb64af8950648c5949c2bcf8641d6b82022-12-22T02:17:09ZengChina Anti-Cancer AssociationCancer Biology & Medicine2095-39412095-39412019-09-0116353054110.20892/j.issn.2095-3941.2018.03802018000380Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57<sup>CDKN1C</sup> and TP53INP1 in mantle cell lymphomaWei Li0Chengfeng BiYating Han1Tian Tian2Xianhuo Wang3Huijing Bao4Xiaoying Xu5Xuhan Zhang6Lu Liu7Weiwei Zhang8Hai Gao9Huaqing Wang10Huilai Zhang11Bin Meng12Xi Wang13Kai Fu14Department of LymphomaDepartment of Cell Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, ChinaDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha 68198, USADepartment of LymphomaDepartment of Laboratory Sciences, Tianjin Medical University, Tianjin 300070, ChinaDepartment of Pathology, Sino-US Center for Lymphoma and Leukemia Research, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, ChinaDepartment of LymphomaDepartment of LymphomaDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha 68198, USADepartment of Cell Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, ChinaCancer Center, Tianjin Union Hospital, Tianjin 300121, ChinaDepartment of LymphomaDepartment of Pathology, Sino-US Center for Lymphoma and Leukemia Research, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, ChinaDepartment of Cell Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, ChinaDepartment of Lymphoma<b>Objective</b> To explore the effect of dysregulation of epigenetic regulator EZH1 and EZH2 on the proliferation in MCL and the underlying mechanisms.<b>Methods</b> In this study, we elucidated the role of EZH1 and EZH2 overexpression by immunohistochemistry and correlated them to clinical outcome in 41 MCL patients. Quantitative real-time PCR and Western blot were applied to confirm the level of EZH1 and EZH2 in well-characterized MCL cell lines which were compared to those of na?ve B cells. Then we manipulated the expression of EZH1 and EZH2 in MCL cells using CRISPR/Cas9 system to directly investigate their functional roles in MCL. We also evaluated the effect of two small molecule selective inhibitors, EPZ005687 and UNC1999, on MCL cell proliferation, cell cycle distribution and apoptosis <i>in vitro</i>. Finally, we performed RNA-sequencing (RNA-Seq) and Chromatin immunoprecipitation (ChIP) assay to further gain insight into the underlying molecular mechanisms.<b>Results</b> We found that EZH2 protein is overexpressed in approximately half of this cohort of MCL cases. More importantly, the overexpression of EZH2 is associated with poor OS in the patients. Nevertheless, simple EZH2 depletion <i>in vitro</i> has little impact on the viability of MCL cells, predominantly because of the consequent up-regulation of EZH1. Consistently, UNC1999, a dual EZH1/2 inhibitor, unlike the EZH2 selective inhibitor EPZ005687, exerts a potent inhibitory effect on MCL cells. Furthermore, we discover <i>CDKN1C</i> and <i>TP53INP1</i> as the two important cell cycle regulators, the expression of which are repressed by EZH1/2 mediated epigenetic regulation and are restored by EZH1/2 dual inhibition.<b>Conclusions</b> Our study suggests that EZH2 participates in the pathogenesis of MCL which may serve as a potential biomarker for prognosis prediction. The dual inhibition of EZH1/2 is a promising therapeutic strategy for MCL.http://www.cancerbiomed.org/index.php/cocr/article/view/1451Mantle cell lymphomaEZH1EZH2CRISPR/Cas9 |
| spellingShingle | Wei Li Chengfeng Bi Yating Han Tian Tian Xianhuo Wang Huijing Bao Xiaoying Xu Xuhan Zhang Lu Liu Weiwei Zhang Hai Gao Huaqing Wang Huilai Zhang Bin Meng Xi Wang Kai Fu Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57<sup>CDKN1C</sup> and TP53INP1 in mantle cell lymphoma Cancer Biology & Medicine Mantle cell lymphoma EZH1 EZH2 CRISPR/Cas9 |
| title | Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57<sup>CDKN1C</sup> and TP53INP1 in mantle cell lymphoma |
| title_full | Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57<sup>CDKN1C</sup> and TP53INP1 in mantle cell lymphoma |
| title_fullStr | Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57<sup>CDKN1C</sup> and TP53INP1 in mantle cell lymphoma |
| title_full_unstemmed | Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57<sup>CDKN1C</sup> and TP53INP1 in mantle cell lymphoma |
| title_short | Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57<sup>CDKN1C</sup> and TP53INP1 in mantle cell lymphoma |
| title_sort | targeting ezh1 2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57 sup cdkn1c sup and tp53inp1 in mantle cell lymphoma |
| topic | Mantle cell lymphoma EZH1 EZH2 CRISPR/Cas9 |
| url | http://www.cancerbiomed.org/index.php/cocr/article/view/1451 |
| work_keys_str_mv | AT weili targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57supcdkn1csupandtp53inp1inmantlecelllymphoma AT chengfengbi targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57supcdkn1csupandtp53inp1inmantlecelllymphoma AT yatinghan targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57supcdkn1csupandtp53inp1inmantlecelllymphoma AT tiantian targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57supcdkn1csupandtp53inp1inmantlecelllymphoma AT xianhuowang targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57supcdkn1csupandtp53inp1inmantlecelllymphoma AT huijingbao targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57supcdkn1csupandtp53inp1inmantlecelllymphoma AT xiaoyingxu targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57supcdkn1csupandtp53inp1inmantlecelllymphoma AT xuhanzhang targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57supcdkn1csupandtp53inp1inmantlecelllymphoma AT luliu targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57supcdkn1csupandtp53inp1inmantlecelllymphoma AT weiweizhang targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57supcdkn1csupandtp53inp1inmantlecelllymphoma AT haigao targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57supcdkn1csupandtp53inp1inmantlecelllymphoma AT huaqingwang targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57supcdkn1csupandtp53inp1inmantlecelllymphoma AT huilaizhang targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57supcdkn1csupandtp53inp1inmantlecelllymphoma AT binmeng targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57supcdkn1csupandtp53inp1inmantlecelllymphoma AT xiwang targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57supcdkn1csupandtp53inp1inmantlecelllymphoma AT kaifu targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57supcdkn1csupandtp53inp1inmantlecelllymphoma |